HLS Therapeutics Inc. (HLS.TO) TSX

Currency In CAD

AD

Valuation

Market Cap110.65M
Enterprise Value148.68M
P/E Ratio-10.35
PEG Ratio-0.17
Price/Sales Ratio1.51
Price/Book Ratio1.69
Enterprise/Revenue2.01
Enterprise/EBITDA6.17

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.15
Operating Margin-0.08
AD

Management Effectiveness

Return On Assets-0.07
Return On Equity-0.14

Income Statement

Revenue56.47M
Revenue/Share1.66
Gross Profit24.01M
EBITDA18.02M
Net Income-12.65M
Diluted EPS-0.4

Balance Sheet

Total Cash13.71M
Total Cash/Share0.4
Total Debt41.84M
Total Debt/Equity0.76
Current Ratio1.05
Book Value Per Share1.62

Price History

52-Week Change-26.16
52-Week High5.62
52-Week Low0
Moving Average 50 Days3.94
Moving Average 200 Days4.32

Statistics

Average Volume68,764
Shares Outstanding30.94M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD